This is the same drug, same old thing that has been working for years, come out with an extended release version and I am guessing the patent stretches out just a little further.  BD 

Approved with a risk evaluation and mitigation strategy (Follows alerts) image

Aug 26 (Reuters) - Johnson and Johnson unit Janssen Pharmaceuticals got U.S. regulatory approval to market its oral pain drug Nucynta ER for moderate to severe chronic pain when an opioid analgesic is needed for extended use.

Nucynta ER is an extended-release version of the company's already approved pain drug Nucynta.

The drug has been approved along with a risk evaluation and mitigation strategy, also known as REMS, to educate prescribers about the potential for abuse, misuse, overdose and addiction from exposure to the drug.


Post a Comment

Google Analytics Alternative